Home・Akciju saraksts・Lantheus Holdings Inc

Lantheus Holdings Inc

Slēgts

SektorsVeselības aprūpe

100.98 -0.08

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

100.52

Max

101.27

Galvenie mērījumi
By Trading Economics
Ienākumi	75M 193M
Pārdošana	11M 388M
P/E Sektora vidējais	23.943 57.366
EPS	1.32
Peļņas marža	49.834
Darbinieki	1,193
EBITDA	-69M 115M

Rekomendācijas
By TipRanks
Rekomendācijas	Neitrāls
Prognoze 12 mēnešiem	+4.56% upside

Dividendes
By Acuity
Nākamie ieņēmumi	2026. g. 5. nov.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-8.6M 6.6B
Iepriekšējā atvēršanas cena	101.06
Iepriekšējā slēgšanas cena	100.98

Ziņu noskaņojums

By Acuity

47%

53%

158 / 340 Rangs Healthcare

Lantheus Holdings Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 20. aug. 19:36 UTC

Lantheus Holdings Inc. shares are lower, impacted by a decline in the Health Care Supplies sub-sector. The asset remains near its one-month range low.

2026. g. 19. aug. 23:26 UTC

Lantheus Holdings Inc. is seeing modest gains in after-market trading, with no specific news identified to explain the price movement.

2026. g. 13. aug. 20:06 UTC

Lantheus Holdings Inc. is moving higher amid overall market gains, despite no specific company news to explain the advance.

2026. g. 12. aug. 23:36 UTC

Lantheus Holdings Inc. shares declined in after-market trading, remaining below their 20-day moving average amid recent inflation data influencing investor sentiment.

2026. g. 3. aug. 19:56 UTC

Social Media

News

Event

Lantheus Holdings Inc. to be acquired by Curium for up to $8 billion, offering $102.50 per share plus contingent value rights. Shares rise amid merger news.

2026. g. 31. jūl. 22:01 UTC

Lantheus Holdings Inc shares are lower in after-market hours amid weak trading conditions, remaining below the 20-day moving average and near a one-month low.

2026. g. 30. jūl. 17:31 UTC

Lantheus Holdings Inc is higher during Thursday's session, driven by overall market momentum, despite earlier downward pressure. The S&P 500 Index is also advancing.

2026. g. 29. jūl. 21:42 UTC

Lantheus Holdings Inc is trading lower in after-market hours, influenced by a decline in the broader market and rising oil prices amid geopolitical tensions.

2026. g. 28. jūl. 19:42 UTC

Social Media

Lantheus Holdings is in talks for a $7 billion acquisition by Curium, with shares declining despite the news and reaching a session low earlier.

2026. g. 27. jūl. 22:51 UTC

News

Lantheus Holdings is in talks for a $7 billion acquisition of Curium. Shares are trading lower in after-market hours amid deal evaluations.

2026. g. 24. jūl. 22:01 UTC

Lantheus Holdings Inc is trading lower in after-market hours, moving toward the lower end of its one-month trading range. No specific news was identified.

2026. g. 23. jūl. 23:02 UTC

Lantheus Holdings Inc. shares are lower in after-market trading, continuing a downward trend since Thursday's close, remaining below the 20-day moving average.

2026. g. 22. jūl. 19:06 UTC

Lantheus Holdings Inc shares are lower today, continuing a decline since Tuesday's close. Broader market sentiment is impacted by rising crude oil prices.

2026. g. 21. jūl. 22:46 UTC

Lantheus Holdings Inc shares are trading higher in after-market hours, supported by a broader market rebound, particularly in the tech sector.

2026. g. 20. jūl. 19:46 UTC

Lantheus Holdings Inc. shares are lower today, declining amid rising oil prices above $90 per barrel, contributing to inflationary pressures globally.

Salīdzinājums

Cenas izmaiņa

Lantheus Holdings Inc Prognoze

Cenas mērķis

By TipRanks

4.56% augšup

Prognoze 12 mēnešiem

Vidējais 105.4 USD 4.56%

Augstākais 115 USD

Zemākais 102.5 USD

Pamatojoties uz 10 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Lantheus Holdings Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

10 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 10 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Lantheus Holdings Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

158 / 340 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Lantheus Holdings Inc

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.